Protein hydrolysate co-ingestion does not modulate 24 h glycemic control in long-standing type 2 diabetes patients

European Journal of Clinical Nutrition

Volumn 63, Issue 1, 2009, Pages 121-126

  Manders, R J F ^a   Praet, S F E ^a   Vikstrom M H ^a   Saris, W H M ^a   van Loon, L J C ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN HYDROLYSATE; GLUCOSE; METFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; LEUCINE; MIDDLE AGED; PROTEIN HYDROLYSATES;

EID: 58149465368     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/sj.ejcn.1602891     Document Type: Article

References (37)

1. ADA (2003). Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26 (Suppl 1), S5-S20.
2. ADA (2006). Standards of medical care in diabetes-2006. Diabetes Care 29 (Suppl 1), S4-S42.
3. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ et al. (2000). Compendium of physical activities: An update of activity codes and MET intensities. Med Sci Sports Exerc 32 (Suppl), S498-S504.
4. Anderson SA, Raiten DJ (eds.) (1992). Safety of Amino Acids Used as Dietary Supplements. Federation of American Societies for Experimental Biology: Bethesda.
5. Ceriello A (2003). The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 46 (Suppl 1), M9-M16.
6. Ceriello A (2005). Postprandial hyperglycemia and diabetes complications: Is it time to treat? Diabetes 54, 1-7.
7. DCCT (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329, 977-986.
8. Del Prato S (2002). In search of normoglycaemia in diabetes: Controlling postprandial glucose. Int J Obes Relat Metab Disord 26 (Suppl 3), S9-S17.
9. Frid AH, Nilsson M, Holst JJ, Bjorck IM (2005). Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. Am J Clin Nutr 82, 69-75.
10. Gannon MC, Nuttall FQ (2004). Effect of a high-protein, low-carbohydrate diet on blood glucose control in people with type 2 diabetes. Diabetes 53, 2375-2382.
11. Gannon MC, Nuttall FQ (2006). Control of blood glucose in type 2 diabetes without weight loss by modification of diet composition. Nutr Metab (London) 3, 16.
12. Halton TL, Hu FB (2004). The effects of high protein diets on thermogenesis, satiety and weight loss: A critical review. J Am Coll Nutr 23, 373-385.
13. Health Council of the Netherlands (HCN) (1999). Safety of amino acid supplementation. Committee on amino acid supplementation. Health Council of the Netherlands: The Hague.
14. Heine RJ, Balkau B, Ceriello A, Del Prato S, Horton ES, Taskinen MR (2004). What does postprandial hyperglycaemia mean? Diabet Med 21, 208-213.
15. Koopman R, Wagenmakers AJ, Manders RJ, Zorenc AH, Senden JM, Gorselink M et al. (2005). Combined ingestion of protein and free leucine with carbohydrate increases postexercise muscle protein synthesis in vivo in male subjects. Am J Physiol Endocrinol Metab 288, E645-E653.
16. Manders RJ, Wagenmakers AJ, Koopman R, Zorenc AH, Menheere PP, Schaper NC et al. (2005). Co-ingestion of a protein hydrolysate and amino acid mixture with carbohydrate improves plasma glucose disposal in patients with type 2 diabetes. Am J Clin Nutr 82, 76-83.
17. Manders RJ, Koopman R, Sluijsmans WE, van den Berg R, Verbeek K, Saris WH et al. (2006a). Co-ingestion of a protein hydrolysate with or without additional leucine effectively reduces post-prandial blood glucose excursions in Type 2 diabetic men. J Nutr 136, 1294-1299.
18. Manders RJ, Praet SF, Meex RC, Koopman R, de Roos AL, Wagenmakers AJ et al. (2006b). Protein hydrolysate/leucine co-ingestion reduces the prevalence of hyperglycemia in type 2 diabetic patients. Diabetes Care 29, 2721-2722.
19. Maran A, Crepaldi C, Avogaro A, Catuogno S, Burlina A, Poscia A et al. (2004). Continuous glucose monitoring in conditions other than diabetes. Diabetes Metab Res Rev 20 (Suppl 2), S50-S55.
20. Maran A, Crepaldi C, Tiengo A, Grassi G, Vitali E, Pagano G et al. (2002). Continuous subcutaneous glucose monitoring in diabetic patients: a multicenter analysis. Diabetes Care 25, 347-352.
21. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ (2001). A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 24, 539-548.
22. Matthews DE (2005). Observations of branched-chain amino acid administration in humans. J Nutr 135 (Suppl), 1580S-1584S.
23. Nair KS, Short KR (2005). Hormonal and signaling role of branched-chain amino acids. J Nutr 135 (Suppl), 1547S-1552S.
24. Newsholme P, Brennan L, Rubi B, Maechler P (2005). New insights into amino acid metabolism, beta-cell function and diabetes. Clin Sci (London) 108, 185-194.
25. Nuttall FQ, Gannon MC (2004). Metabolic response of people with type 2 diabetes to a high protein diet. Nutr Metab (London) 1, 6.
26. Polonsky KS, Sturis J, Bell GI (1996). Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 334, 777-783.
27. Porte Jr D, Kahn SE (2001). beta-cell dysfunction and failure in type 2 diabetes: Potential mechanisms. Diabetes 50 (Suppl 1), S160-S163.
28. Poscia A, Mascini M, Moscone D, Luzzana M, Caramenti G, Cremonesi P et al. (2003). A microdialysis technique for continuous subcutaneous glucose monitoring in diabetic patients (part 1). Biosens Bioelectron 18, 891-898.
29. Praet SF, Manders RJ, Meex RC, Lieverse AG, Stehouwer CD, Kuipers H et al. (2006). Glycemic instability is an underestimated problem in type 2 diabetes. Clin Sci (London) 111, 119-126.
30. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321, 405-412.
31. UKPDS (1998a). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 854-865.
32. UKPDS (1998b). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837-853.
33. Van Loon LJ (2007). Amino acids as pharmaco-nutrients for the treatment of type 2 diabetes. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry 7, 39-48.
34. van Loon LJC, Kruishoop M, Menheere PPCA, Wagenmakers AJM, Saris WHM, Keizer HA (2003). Amino acid ingestion strongly enhances insulin secretion in patients with long-term type 2 diabetes. Diabetes care 26, 625-630.
35. Varalli M, Marelli G, Maran A, Bistoni S, Luzzana M, Cremonesi P, et al. (2003). A microdialysis technique for continuous subcutaneous glucose monitoring in diabetic patients (part 2). Biosens Bioelectron 18, 899-905.
36. Wentholt IM, Vollebregt MA, Hart AA, Hoekstra JB, DeVries JH (2005). Comparison of a needle-type and a microdialysis continuous glucose monitor in type 1 diabetic patients. Diabetes Care 28, 2871-2876.
37. Xu G, Kwon G, Cruz WS, Marshall CA, McDaniel ML (2001). Metabolic regulation by leucine of translation initiation through the mTOR-signaling pathway by pancreatic beta-cells. Diabetes 50 353-360.